Human Technopole continues its dialogue with Italian Research Hospitals (IRCCS).
Milan, 15 January – Human Technopole is an open hub for the entire Italian scientific community. This is how Marco Simoni – President of Human Technopole – described the Foundation during the event “Le strategie di ricerca della Fondazione Human Technopole: quali opportunità per gli IRCCS della Lombardia“, held at Palazzo Italia and organized by Assolombarda.
President Marco Simoni, Maria Grazia Magro (Head of Strategy and Scientific Affairs of Human Technopole) and Giuseppe Testa (Head of Neurogenomics Centre) explained the next steps of Human Technopole to almost 40 Research Hospitals’ General Director and Scientific Directors including Maria Chiara Carrozza (Scientific Director of Fondazione Don Gnocchi ), Alberto Mantovani (Scientific Director of Humanitas) and Fabrizio Tagliavini (Scientific Director of the Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta). Sergio Dompé – Vice President Life Sciences, Assolombarda – underlined Human Technopole’s innovative scope, its impact on Lombardy’s economic income and expressed the strong contribution that Assolombarda wants to give to the IRCCSs of Lombardy.
Human Technopole’s openness, its positive effects for the whole country and common objectives with the IRCCSs are the concepts stressed in Marco Simoni’s speech; Maria Grazia Magro highlighted the dialogue carried out with the representatives of the Italian scientific community in the past months when more than half of the Italian IRCCSs were met individually by Human Technopole. Giuseppe Testa focused on the work of his centre and on the synergies that can be implemented with the scientific community in the near future.
Yesterday, Open HT was announced – the first event organized by Human Technopole addressed to the scientific community, which will be the first, shared occasion of systematic dialogue on the Foundation’s development strategies.
Share:
You could also like:
-
Two ERC-funded projects to search for tumours’ weaknesses
Human Technopole has once again been awarded by Europe’s prestigious public body for funding of scientific research conducted within the European Union, the European Research Council (ERC), for two projects on the origin of tumours, their evolution and the development of resistance to therapies. The two studies could contribute to the identification of new anti-cancer targeted […]
-
COVID-19: How SARS‑CoV‑2 Enters Human Cells
A study by the University of Padua and Human Technopole, together with the University of Milan and the European Institute of Oncology, published in Cell Reports Medicine, reveals that SARS-CoV-2, the virus that causes COVID-19, binds the RAGE receptor present on the surface of specific human immune cells to penetrate them and pathologically alter their function. This study also shows how the involvement of RAGE, previously known only in the context of other pathophysiological conditions, such as obesity and diabetes, is implicated in the degree of severity with which COVID-19 can manifest.
-
Italy joins the iCARE4CVD consortium
The Human Technopole and Mario Negri institute for Pharmacological Research are among 33 leading international partners who have joined forces to better understand cardiovascular diseases and optimise future prevention and treatment.
-
Study tour “Austrian Life Science Innovation Ecosystem” in Vienna
The Human Technopole Centre for Innovation and Technology Transfer (CITT) continues its international promotion activities by learning about foreign innovation ecosystems. From 28 to 30 November 2023, CITT is organising a study tour to meet the leading players in basic and applied research within the Austrian ecosystem, with the support of the Italian Embassy in Vienna and the Italian Trade Agency.
-
Annotating human genes: where do we stand now?
In a perspective article published in Nature, Piero Carninci and colleagues discuss the status of human gene annotation and how high-throughput RNA sequencing technologies have accelerated the discovery of non-coding RNA genes with unknown functions and will promote the completion of the human gene catalogue.